Erratum: Idiopathic membranoproliferative glomerulonephritis: Does it exist (Nephrology Dialysis Transplantation (2012) 27: 12 (4288-4294) DOI: 10.1093/ndt/gfs288);Idiopathic membranoproliferative glomerulonephritis: Does it exist?

Nephrology Dialysis Transplantation

Volumn 27, Issue 12, 2012, Pages 4288-4294

  Fervenza, Fernando C ^a   Sethi, Sanjeev ^a   Glassock, Richard J ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C3 glomerulonephritis; membranoproliferative; complement abnormalities; dense deposit disease; glomerular diseases; glomerulonephritis

Indexed keywords

COMPLEMENT COMPONENT C3;

CLASSIFICATION ALGORITHM; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; DENSE DEPOSIT DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNE COMPLEX DEPOSITION; IMMUNE COMPLEX NEPHRITIS; IMMUNE DYSREGULATION; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; KIDNEY STRUCTURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84871193435     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft058     Document Type: Erratum

References (51)

1. Habib R, Michielsen P, De Montera E et al. Clinical, microscopic and electron microscopic data in the nephrotic syndrome of unknown origin. In: Wostenholme GEW, Cameron MP (eds). Ciba Foundation Symposium-Renal Biopsy: Clinical and Pathological Significance. London: Churchill, 1961, pp. 70-102.
2. Royer P, Habib R, Vermeil G et al. Prolonged glomerulonephrtis in children: apropos of 4 anatomcial aspects revealed by renal biopsy. Ann Pediatr 1962; 9: 173-187.
3. Weller RO, Nester B. Histological reassessment of three kidneys originally described by Richard Bright in 1827-1836. Brit Med J 1972; 2: 761-763.
4. West CD, McAdams AJ, McConvilkle JM et al. Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis; clinical and pathologic characteristics. J Pediatr 1965; 67: 1089-1097.
5. Cameron JS, Glasgow EF, Ogg CS et al. Membranoproliferative glomerulonephritis and persistent hypocomplementemia. Br Med J 1970; 4: 7-14.
6. Kumatowska I, Jedrzejka D, Malyska a et al. Trends in the incidence of biopsy-proven glomerualr disease in the adult population in central Poland in the years 1990-2010. Kidney Blood Press Res 2012; 35: 254-258.
7. Hurtado A, Johnson RJ. Hygeine hypothesis and prevalence of glomerulonephritis. Kidney Int (Supplement) 2005; 97: S62-S67.
8. Jennette JC, Olson LJ, Schwartz MM et al. (ed). Heptinstall's Pathology of the Kidney. Philadelphia: Lippincott Williams & Wilkins, 2007.
9. Kumar V, Abul AK, Fausto N et al. (ed). Pathologic Basis of Disease. Philadelphia: Elsevier Saunders, 2010.
10. Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995; 47: 643-656.
11. Burkholder PM, Marchand A, Krueger RP. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab Invest 1970; 23: 459-479.
12. Strife CF, McEnery PT, McAdams AJ et al. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7: 65-72.
13. Anders D. [Membranoproliferative glomerulonephritis]. Dtsch Med Wochenschr 1977; 102: 1295-1296.
14. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31: 341-348.
15. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 2012; 366: 1119-1131.
16. Sethi S, Fervenza FC, Zhang Y et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6: 1009-1017.
17. Sethi S, Gamez JD, Vrana JA et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960.
18. Brigani EM, Dowling J, Finlay M et al. The incidence of biopsyproven glomerulonephritis in Australia. Nephrol Dial Transplant 2001; 16: 1364-1367.
19. Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000; 35: 157-165.
20. McGrogan A, Franssen CEM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430.
21. Swaminathan S, Leung N, Lager DJ et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephol 2006; 1: 483-487.
22. Braden GL, Mulhern JG, O'Shea MH et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35: 878-883.
23. Zhou FD, Zhao MH, Zou WZ et al. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 2009; 24: 870-876.
24. Roccatello D, Fornasieri A, Giachino O et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49: 69-82.
25. Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2005; 14: 396-403.
26. Martinelli R, Noblat AC, Brito E et al. Schistosoma mansoniinduced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35: 1227-1233.
27. Ades L, Akposso K, Costa de Beauregard MA et al. Bacterial endocarditis associated with crescentic glomerulonephritis in a kidney transplant patient: first case report. Transplantation 1998; 66: 653-654.
28. Vella J, Carmody M, Campbell E et al. Glomerulonephritis after ventriculo-atrial shunt. QJM 1995; 88: 911-918.
29. Maripuri S, Grande JP, Osborn TG et al. Renal involvement in primary Sjogren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009; 4: 1423-1431.
30. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
31. Sethi S, Zand L, Leung N et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5: 770-782.
32. Nasr SH, Satoskar A, Markowitz GS et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20: 2055-2064.
33. Nasr SH, Markowitz GS, Stokes MB et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Intl 2004; 65: 85-96.
34. Smith RJ, Alexander J, Barlow PN et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456.
35. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729-740.
36. Ferreira VP, Pangburn MK, Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010; 47: 2187-2197.
37. Habbig S, Mihatsch MJ, Heinen S et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75: 1230-1234.
38. Servais A, Fremeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199.
39. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446.
40. Gale DP, de Jorge EG, Cook HTet al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801.
41. Abrera-Abeleda MA, Nishimura C, Smith JL et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589.
42. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular profile, treatment and follow-up. Kidney Int 2012 doi: 10.1038/ki.2012.212 [Epub ahead of print].
43. Appel GB, Cook HT, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392-1403.
44. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 2007; 16: 204-212.
45. Fakhouri F, Fremeaux-Bacchi V, Noel LH et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494-499.
46. Goldberg RJ, Nakagawa T, Johnson RJ et al. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010; 56: 1168-1174.
47. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
48. Bridoux F, Desport E, Fremeaux-Bacchi V et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephro 2011; 6: 2165-2174.
49. Sethi S, Sukov WR, Zhang Y et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56: 977-982.
50. Lorenz EC, Sethi S, Leung N et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010; 77: 721-728.
51. Vernon KA, Gale DP, de Jorge EG et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11: 152-155.